[go: up one dir, main page]

AR024463A1 - SOMATOSTATINE AGONISTS - Google Patents

SOMATOSTATINE AGONISTS

Info

Publication number
AR024463A1
AR024463A1 ARP000103155A ARP000103155A AR024463A1 AR 024463 A1 AR024463 A1 AR 024463A1 AR P000103155 A ARP000103155 A AR P000103155A AR P000103155 A ARP000103155 A AR P000103155A AR 024463 A1 AR024463 A1 AR 024463A1
Authority
AR
Argentina
Prior art keywords
trp
cys
group
tyr
alkyl
Prior art date
Application number
ARP000103155A
Other languages
Spanish (es)
Original Assignee
Scient S C R A S Soc De Conseils De Rech S Et D Applic S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scient S C R A S Soc De Conseils De Rech S Et D Applic S filed Critical Scient S C R A S Soc De Conseils De Rech S Et D Applic S
Publication of AR024463A1 publication Critical patent/AR024463A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)

Abstract

Se refiere a péptidos cíclicos de formula (1): X-A1-ciclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y o su sal farmacéuticamente aceptable, en donde: X es H, formula (2) oformula (3); A1 y A3 son cada uno independientemente el isomero D- o L- de un aminoácidoselecc ionado entre el grupo que consiste en Phe, Tyr, Tyr(I), Trp,3-Pal, 4-Pal, Cpa y NaI; A4 es L-Trp, D-Trp, L-beta-metil-Trp o D-beta-metil-Trp; A6 es -NH-(CHR1)n-CO-, donde n es 2, 3 o 4; A7 es L- o D-Cys; A8 es elisomero D o L de un aminoácidoselecci onado entre el grupo que consiste en Phe, Tyr, Tyr(I), Trp, NaI, Cpa, Val, Leu, IIe, Ser y Thr; Y es NR2R3 donde R2 y R3son cada uno independientemente H o alquilo C1-5; R1 se selecciona entre el grupo que consiste en H, alquilo C1-4 y-CH2-arilo; en donde dicho arilo es unaporcion optativamente sustituida seleccionada entre el grupo que consiste en fenilo, 1-naftilo y 2-naftilo, en donde dicha porcion optativamente sustituida esoptativamente sustituida con uno o más sustituyentescada uno selec cionado independientemente entre el grupo que consiste en alquiloC1-6, alquenilo C2-6,alquinilo C2-6, arilo, arilalquilo C1-6, alcoxi C1-6, -N(R4R5), -COOH, -CON(R4R5), halo, -OH, -CN, y -NO2; R4 y R5 cada uno es, independientementepara cadaaparicio n, H o alquilo C1-3; donde el Cys de A2 está unido al Cys de A7 por un enlace di-sulfuro formado de los grupos tiol de cada Cys; composicionesfarmacéuticas que comprenden dichos péptidos y el uso de las mismas como un agonista delos subtipos del rec eptor de somatostatina. Los péptidos de la presentese unen selectivamente al tipo 5 del receptor de los subtipos de somatostatina y producen un efecto agonista de los receptores de subtipo de somatostatina alas cuales se unenlos péptidos.Refers to cyclic peptides of formula (1): X-A1-cycle (D-Cys-A3-A4-Lys-A6-A7) -A8-Y or its pharmaceutically acceptable salt, wherein: X is H, formula ( 2) oformula (3); A1 and A3 are each independently the D- or L- isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr (I), Trp, 3-Pal, 4-Pal, Cpa and NaI; A4 is L-Trp, D-Trp, L-beta-methyl-Trp or D-beta-methyl-Trp; A6 is -NH- (CHR1) n-CO-, where n is 2, 3 or 4; A7 is L- or D-Cys; A8 is the D or L elisomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr (I), Trp, NaI, Cpa, Val, Leu, IIe, Ser and Thr; Y is NR2R3 where R2 and R3 are each independently H or C1-5 alkyl; R1 is selected from the group consisting of H, C1-4 alkyl and -CH2-aryl; wherein said aryl is an optionally substituted portion selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl, wherein said optionally substituted portion is optionally substituted with one or more substituents each one independently selected from the group consisting of C1-alkyl. 6, C2-6 alkenyl, C2-6 alkynyl, aryl, C1-6 arylalkyl, C1-6 alkoxy, -N (R4R5), -COOH, -CON (R4R5), halo, -OH, -CN, and -NO2 ; R4 and R5 each is, independently for each space n, H or C1-3 alkyl; where the Cys of A2 is linked to the Cys of A7 by a di-sulfide bond formed from the thiol groups of each Cys; Pharmaceutical compositions comprising said peptides and their use as an agonist of the subtypes of the somatostatin receptor. The peptides of the present selectively bind to type 5 receptor somatostatin subtypes and produce an agonist effect of somatostatin subtype receptors to which peptides bind.

ARP000103155A 1999-06-25 2000-06-23 SOMATOSTATINE AGONISTS AR024463A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14102899P 1999-06-25 1999-06-25

Publications (1)

Publication Number Publication Date
AR024463A1 true AR024463A1 (en) 2002-10-02

Family

ID=22493842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103155A AR024463A1 (en) 1999-06-25 2000-06-23 SOMATOSTATINE AGONISTS

Country Status (14)

Country Link
EP (1) EP1189942A1 (en)
JP (1) JP4041311B2 (en)
CN (1) CN1367792A (en)
AR (1) AR024463A1 (en)
AU (1) AU770958B2 (en)
BR (1) BR0011919A (en)
CA (1) CA2377265A1 (en)
CZ (1) CZ20014534A3 (en)
HU (1) HUP0201696A3 (en)
IL (1) IL146941A0 (en)
MX (1) MXPA01013127A (en)
PL (1) PL352763A1 (en)
RU (1) RU2263677C2 (en)
WO (1) WO2001000676A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60220157T2 (en) * 2001-03-06 2008-01-17 Il Consorzio Ferrara Richerche PROCESS FOR MODULATING THE PROLIFERATION OF MEDULLARY THYROID CARCINOMA CELLS
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
EP1522311A1 (en) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of somatostatin or analogs thereof for the preparation of a medicament for the regulation of ovarian follicles reserve by non menopausaled women
US8470770B2 (en) 2007-04-30 2013-06-25 Technion Research & Development Foundation Ltd. Antimicrobial agents
EP2142257A2 (en) * 2007-04-30 2010-01-13 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
CA2781402C (en) * 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
WO2011151782A1 (en) 2010-06-02 2011-12-08 Preglem Sa A role for somatostatin to modulate initiation of follicular growth in the human ovary
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014144231A1 (en) * 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE14226T1 (en) * 1981-12-24 1985-07-15 Ciba Geigy Ag CYCLIC OCTAPEPTIDES AND PHARMACEUTICAL PREPARATIONS THEREOF, AND PROCESSES FOR THE MANUFACTURE THE SAME AND THEIR USE.
HU207104B (en) * 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
DE69432758T2 (en) * 1993-08-09 2004-02-19 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. THERAPEUTICALLY EFFECTIVE PEPTIDE DERIVATIVES
WO1998024807A2 (en) * 1996-12-04 1998-06-11 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin antagonists
ES2195333T3 (en) * 1997-05-01 2003-12-01 Cedars Sinai Medical Center METHOD TO TREAT HYPERPROLACTINEMIA AND PROLACTINOMAS.
PT980253E (en) * 1997-05-13 2004-08-31 Conseils De Rec Appl Scient S SOMATOSTATIN AND SOMATOSTATIN AGONISTS TO TREAT INSULIN INSULIN AND X SYNDROME
WO1998051330A1 (en) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Method and compositions for treating hyperlipidemia and other conditions
ES2202864T3 (en) * 1997-05-13 2004-04-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. AGOMISTS OF THE SOMATOSTATINE TO DECREASE BODY WEIGHT.

Also Published As

Publication number Publication date
MXPA01013127A (en) 2002-11-04
BR0011919A (en) 2002-03-19
AU6200000A (en) 2001-01-31
CZ20014534A3 (en) 2002-06-12
EP1189942A1 (en) 2002-03-27
JP4041311B2 (en) 2008-01-30
HUP0201696A3 (en) 2002-10-28
PL352763A1 (en) 2003-09-08
AU770958B2 (en) 2004-03-11
IL146941A0 (en) 2002-08-14
JP2003503369A (en) 2003-01-28
WO2001000676A1 (en) 2001-01-04
HUP0201696A2 (en) 2002-09-28
CN1367792A (en) 2002-09-04
CA2377265A1 (en) 2001-01-04
RU2263677C2 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
AR024463A1 (en) SOMATOSTATINE AGONISTS
TR200200252T2 (en) Chimeric polypeptides, method and use for their production
CA2060034A1 (en) Tumour growth-inhibiting somatostatin analogues, pharmaceutical compositions containing them and process for preparing same
TR199901028T2 (en) Analogue oxytocin heptapeptide.
LV5794A4 (en) Nonapeptide with bombesin antagonist ipasibam
UY27109A1 (en) DERIVATIVES OF QUINAZOLONA AS ANTAGONISTS OF ADRENERGIC RECEPTORS ALFA-1A / B
RU2014137107A (en) PEPTIDOMIMETIC MACROCYCLES
AR034132A1 (en) SOMATOSTATINE ANALOGS, A PROCESS FOR PRODUCTION AND PHARMACEUTICAL COMPOSITION
CY1110243T1 (en) NPYY5 COMPETITORS
ATE509618T1 (en) NANOPARTICLE-SHAPED COMPOSITIONS HAVING A PEPTIDE AS A SURFACE STABILIZER
ES2090143T3 (en) GEM-DIPHOSPHONIC ACIDS, A PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
KR910000178A (en) Arthritis Treatment
PE20221328A1 (en) CYCLIC PEPTIDES SPECIFIC TO DIAMINE-BINDED RECEPTORS
AR048949A1 (en) CONJUGATED CAMPTOTECHINE IN POSITION 7 WITH INTEGRINE ANTAGONISTS
RU2002101732A (en) Somatostatin Agonists
NZ335879A (en) Somatostatin antagonist peptides having a D-amino acid at the second residue
ATE546461T1 (en) GNRH NON-MAMMAL ANALOGUE AND USE FOR REGULATION OF FERTILITY AND PREGNANCY
AR035942A1 (en) SOMATOSTATIN ANTAGONISTS, AN IN VITRO METHOD OF LINKING ONE OR MORE SOMATOSTATIN RECEPTORS, USE OF SUCH ANTAGONISTS FOR THE PREPARATION OF MEDICINES AND AN IN VITRO METHOD FOR THE PRODUCTION OF CELL PICTURES THAT HAVE SUCH RECEPTORS.
AR004497A1 (en) AN ANALOGUE CYCLIC HEXAPEPTIDE OF SOMATOSTATINA, PROCEDURE TO PREPARE THEM AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THE USE OF SUCH HEXAPEPTIDE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION.
GB1435384A (en) Psychopharmacologically active peptides
CL2004001579A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ANALOG OF SOMATOSTATIN AND TARTARIC ACID, WHERE THE COMPOSITION HAS THE REGULATED PH BETWEEN 4 AND 4.5 AND THE ACTIVE COMPOUND IS L CYCLE [{4- (NH2-C2H4-NH-CP-O) PRO} - PHG-DTRP-LYS-TYR (4-BZL) -PHE]; AND ITS USE FOR PREPA
DE3863560D1 (en) PEPTIDE DERIVATIVES OF CCK8, THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR026068A1 (en) MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY.
AR116636A1 (en) RADIOPHARMACES TARGETED AT GRPR AND USES OF THEM
BR112022003359A2 (en) Peptide amide composition and method of preparation thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure